Methods
Glucose Abnormalities, T2DM, acute coronary syndrome
MYOCARDIAL INFARCTION, BLIND, ACUTE CORONARY SYNDROME
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI) was a randomized, double blind, placebo-controlled trial conducted at the Cardiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, investigating whether empagliflozin may have beneficial effects on the myocardial function in patients with a recent acute coronary syndrome and newly detected IGT and T2DM. The trial protocol has been previously described in detail [
Changes in insulin and glucose levels during the OGTT at the three different time points. P-values are by Mann-Whitney U-test